Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that the following clinical and preclinical abstracts are expected to be the subject of oral or poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:

-- "Dendritic and T cell functions in patients with metastatic hormone-

refractory prostate cancer treated with GVAX immunotherapy for prostate

cancer and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session)

- Oral presentation scheduled for Monday, April 14, 2008 at 1:25 p.m.

-- "CTLA-4 blockade for hormone refractory prostate cancer: dose-dependent

induction of CD8+ T cell activation and clinical responses" (Abstract

#2539, Clinical Immunotherapy Session) - Oral presentation scheduled

for Monday, April 14, 2008 at 1:40 p.m.

-- "Increased doses of an anti-CD30 antibody, MDX-060, results in

prolonged progression free survival in subjects with CD30 positive

lymphoma" (Abstract #5525, Phase 2 and 3 Clinical Trials 3: Blood,

Lung, Brain/CNS and Sarcoma Session) - Poster session scheduled for

Wednesday, April 16, 2008 at 8:00 a.m.

-- "Preclinical development of anti B7-H4 therapeutic antibodies"

(Abstract #4986, Developmental Immunotherapy Session) - Oral

presentation scheduled for Tuesday, April 15, 2008 at 2:25 p.m.

-- "Human antibody conjugates of potential utility for prostate cancer

therapy: a comparison of MGBA conjugates with antibodies targeting a

cell surface target (prostate-specific membrane antigen) and an extra-

cellular target (Mindin/RG1)" (Abstract #4062, Immunoconjugates,

Peptides, and Protein Therapeutics Session) - Poster session scheduled

for Tuesday, April 15, 2008 at 8:00 a.m.

-- "Efficacy and safety of a human anti-CD70 antibody-MGBA conjugate"

(Abstract #4061, Immunoconjugates, Peptides, and Protein Therapeutics

Session) - Poster session scheduled for Tuesday, April 15, 2008 at 8:00


-- "Mechanism of activation of a human anti-CD70 antibody-MGBA conjugate

and efficacy in a nude rat model of renal carcinoma" (Abstract #4057,

Immunoconjugates, Peptides, and Protein Therapeutics Session) - Poster

session scheduled for Tuesday, April 15, 2008 at 8:00 a.m.

-- "Ptk7 as a direct and tumor stroma target in multiple solid

malignancies" (Abstract #1526, Targets and Screening Approaches

Session) - Poster session scheduled for Sunday, April 13, 2008 at 1:00


Abstracts and information about the AACR and its Annual Meeting may be found at

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
2. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
3. Medarex Announces Completion of Sale of Shares in Genmab A/S
4. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
5. Medarex Announces Election of Marc Rubin as New Board Member
6. Medarex to Present at the UBS Global Life Sciences Conference
7. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
8. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
9. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
10. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
11. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
Post Your Comments:
(Date:10/8/2015)... 2015 Global Biologics and ... and Biosimilars industry . --> Big ... Biosimilars Industry 2015 Deep Market Research Report, Size, ... professional and depth research report on Global ... ) , --> ) , ...
(Date:10/8/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, today announced its schedule of ... in the month of October: Stem Cell ... will be presenting at the annual Partnering Forum, part ... be held October 7-9 in La Jolla, ...
(Date:10/8/2015)... ... October 08, 2015 , ... ... an exclusive license agreement to develop and commercialize intellectual property rights belonging to ... agreement from February 2009, and affords exclusive worldwide rights to intellectual property based ...
(Date:10/7/2015)... ... October 07, 2015 , ... Neil Riordan, PhD to Discuss Medicinal ... October 8th, at Mar-a-Lago from 3:50 pm to 4:30 pm. , Dr. Riordan is ... , He is the Co-Founder and Chief Science Officer of the ...
Breaking Biology Technology:
... /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, TSX:YM), today announced that ... units at an issue price of US $1.20 for gross ... one common share and one half common share purchase warrant. Each whole ... until March 10, 2015 . , ...
... March 10 Bone Biologics, Inc. announced today ... shares from the Musculoskeletal Transplant Foundation (MTF). MTF now ... financing, MTF also provided a line of credit to ... by MTF that have allowed Bone Biologics, Inc. to ...
... ... ... ... ...
Cached Biology Technology:
(Date:9/28/2015)... 28, 2015 CLEAR, the leading ... expedited traveler service is coming to Austin-Bergstrom ... bringing a frictionless experience, serious speed and ... "CLEAR offers our travelers an expedited security ... Jim Smith , Executive Director, Austin-Bergstrom ...
(Date:9/28/2015)... JOSE, Calif. , Sept. 28, 2015 ... of human interface solutions, today announced that Lenovo has ... touch fingerprint sensor, FS4202, for its latest smartphone, the ... secure, password-free access to unlock the device and provide ... The feature-rich Natural ID FS4202 sensor ...
(Date:9/10/2015)... This report provides detailed descriptions of the sensor types ... types that will dominate in the future. Many product ... technology hype curve in the last five years before ... all of them is the prominence of sensor options ... Sensors collect data about the physical and chemical properties ...
Breaking Biology News(10 mins):
... Society today commends President Obama,s decision to sign a ... scientific evidence is used in the development of solutions ... memorandum rightly places science at the forefront of informing ... of solutions to issues such as enhancing energy security, ...
... of proteins, the molecular machines that drive all life, also ... study, in the journal Structure , reveals that after ... of innovation. The active regions of many proteins, called domains, ... host of structures that had never been seen before. This ...
... to treat critical limb ischemia in peripheral arterial ... thwarted by restenosis (the re-narrowing of the artery ... need for repeat treatments and the continued progression ... and amputation. Interventional radiologists have been studying a ...
Cached Biology News:
ma. plate stack height 70mm...
Rotor for four tube-loaded buckets; ma RCF 2550g; sold without buckets...
CQCS kit for etra KR 4i , (other units)....
A compact, high-speed single tube reader unit designed for benchtop 2D barcode reading. The unit can be used with all of ABgene's 2D barcoded tubes, including the 2ml CryoCode tube....
Biology Products: